pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

44 catalysts · 13 phase 2 completion · 10 phase 1 completion · 8 phase 2 initiation · 4 phase 3 initiation · 4 phase 1 initiation · 2 phase 0 trial completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: major-depression×TA: immunology×TA: pulmonology×clear all
type
  • phase 2 completion13
  • phase 1 completion10
  • phase 2 initiation8
  • phase 3 initiation4
  • phase 1 initiation4
  • phase 0 trial completion2
  • phase 1 2 completion1
  • phase 3 completion1
  • constraining patent expiry europe1
  • therapy area
    • Oncology127
    • Infectious Disease38
    • Cardiology36
    • Immunology28
    • Dermatology26
    • Pulmonology18
    • Women's Health15
    • Ophthalmology14
    • Pain11

    Week of Apr 20, 2026

    5
    ›Apr 26, 2026phase 2 completion91d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 initiation91d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 initiation91d agoStarmab Biology (Suzhou) Co Ltd — XJ-103 (Phase II Trial Initiation)XJ-103

    Therapy area: Respiratory. Indication: Streptococcal Pneumonia

    full page →XJ-103 →source: globaldata
    ›Apr 26, 2026phase 3 completion91d agoHomi Bhabha Cancer Hospital Research Centre — megestrol (Phase III Trial Completion)megestrol

    Therapy area: Central Nervous System, Gastrointestinal, Genito Urinary System, Respiratory. Indication: Anorexia Nervosa, Unspecified Gastrointestinal Disorders, Unspecified Genito Urinary Disorders, Unspecified Respiratory Disorders

    full page →megestrol →source: globaldata
    ›Apr 26, 2026phase 3 initiation91d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

    Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

    full page →zanubrutinib →source: globaldata

    Week of Apr 27, 2026

    39
    ›Apr 27, 2026phase 1 completion90d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

    Therapy area: Immunology. Indication: Unspecified Immunological Disorders

    full page →PTC-844 →source: globaldata
    ›Apr 27, 2026phase 1 completion
    90d ago
    Fortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

    Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

    full page →balinatunfib →source: globaldata
    ›Apr 27, 2026phase 1 initiation90d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 2 initiation90d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 3 initiation90d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →abatacept →source: globaldata
    ›Apr 27, 2026phase 3 initiation90d agoGan & Lee Pharmaceuticals Co Ltd — bofanglutide (Phase III Trial Initiation)bofanglutide

    Therapy area: Respiratory. Indication: Obstructive Sleep Apnea

    full page →bofanglutide →source: globaldata
    ›Apr 28, 2026phase 1 completion89d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

    Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

    full page →clarithromycin →source: globaldata
    ›Apr 28, 2026phase 1 initiation89d agoShanghai Argo Pharmaceutical Co Ltd — BW-20805 (Phase I Trial Initiation)BW-20805

    Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

    full page →BW-20805 →source: globaldata
    ›Apr 28, 2026phase 1 initiation89d agoShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)HN-2302

    Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)

    full page →HN-2302 →source: globaldata
    ›Apr 28, 2026phase 2 completion89d agoInonu University — albumin gel- and platelet- rich fibrin (Phase II Trial Completion)albumin gel- and platelet- rich fibrin

    Therapy area: Immunology, Mouth and Dental Disorders. Indication: Inflammation, Periodontal Disease, Periodontitis

    full page →albumin gel- and platelet- rich fibrin →source: globaldata
    ›Apr 28, 2026phase 2 initiation89d agoInstitute of Medical Sciences of the Banaras Hindu University — ropivacaine (Phase II Trial Initiation)ropivacaine ER

    Therapy area: Central Nervous System, Respiratory. Indication: Pleural Disease, Post-Operative Pain

    full page →ropivacaine ER →source: globaldata
    ›Apr 28, 2026phase 2 initiation89d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 29, 2026phase 2 completion88d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 initiation88d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation88d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation88d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 3 initiation88d agoChia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)TQH-2722

    Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis

    full page →TQH-2722 →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe87d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoUniversity of Southern California — methylprednisolone (Phase 0 Trial Completion)MEDROL

    Therapy area: Immunology. Indication: Drug Hypersensitivity Reactions

    full page →MEDROL →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoDongguan Traditional Chinese Medicine Hospital — undisclosed traditional Chinese medicine (Phase I Trial Completion)undisclosed traditional Chinese medicine

    Therapy area: Immunology, Musculoskeletal Disorders. Indication: Osteoporosis, Rheumatoid Arthritis, Sarcopenia

    full page →undisclosed traditional Chinese medicine →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoCheng Du Sheng Nuo Biotec Co Ltd — CIGB-814 (Phase I Trial Completion)CIGB-814

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →CIGB-814 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

    Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

    full page →(acetaminophen + ibuprofen) →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

    Therapy area: Respiratory. Indication: Streptococcal Pneumonia

    full page →pneumococcal (20-valent) vaccine →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

    Therapy area: Immunology. Indication: Inflammation

    full page →FT-2109 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

    Therapy area: Immunology. Indication: Inflammation

    full page →FT-2109 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

    Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

    full page →HLK-0006 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

    Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

    full page →IASO-782 →source: globaldata
    ›Apr 30, 2026phase 1 2 completion87d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

    Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

    full page →M-701 →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →UA-021 →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →telitacicept →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

    Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

    full page →autologous regulatory T cells →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

    Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

    full page →dupilumab →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

    Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

    full page →ozonated oil →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →tozorakimab →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

    Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

    full page →norepinephrine →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

    Therapy area: Immunology. Indication: Inflammation

    full page →SSJG-009 →source: globaldata
    ›Apr 30, 2026phase 2 completion87d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Respiratory. Indication: Cough

    full page →LIDOCAINE →source: globaldata
    $FTRE19.52+0.10%
    $CPIX6.6100-5.37%
    $ECL268.75+2.13%
    $MRK131.07+0.45%
    $AZN169.26+0.59%